

THE LANCET

Rheumatology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Hausmann J S, Kennedy K, Simard J F, et al. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. *Lancet Rheumatol* 2021; published online July 22. [https://doi.org/10.1016/S2665-9913\(21\)00175-2](https://doi.org/10.1016/S2665-9913(21)00175-2).

Supplementary Materials

COVID-19 Rheumatology Patient Experience Survey

Start of Block: Default Question Block

Q1 The COVID-19 Global Rheumatology Alliance is conducting a study to understand how COVID-19 (novel Coronavirus disease, also called SARS-CoV-2) affects adults and children with rheumatic diseases throughout the world. Adults (aged 18 and over) and parents of children with rheumatic disease are invited to participate (whether or not you or your child have been diagnosed with COVID-19). All the information we collect is anonymous. Our aim is to help improve the care of patients with rheumatic diseases during this pandemic. Have questions? Visit our website at rheum-covid.org or email us at rheum.covid.patient.registry@gmail.com.



Q2 Will you be completing the survey for yourself, or on behalf of your child with rheumatic disease?

- For myself (adult aged 18 and over) (1)
 - For my child (2)
-

Display This Question:

If Will you be completing the survey for yourself, or on behalf of your child with rheumatic disease? = For my child

Q3 As a parent or caregiver of a child with a rheumatic disease, please answer all questions on behalf of your child. Remember, when questions ask about "YOU," we're really asking about YOUR CHILD. Thanks for helping us out!



Q4 What is your rheumatologic disease diagnosis (check all that apply)?

- ANCA-associated vasculitis (e.g., granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), EGPA) (1)
- Ankylosing spondylitis (2)
- Anti-phospholipid antibody syndrome (3)
- Autoinflammatory disease (including TRAPS, CAPS, FMF) (4)
- Behcet's syndrome (5)
- Chronic recurrent multifocal osteomyelitis (CRMO) (6)
- Dermatomyositis, polymyositis, or other inflammatory muscle diseases (7)
- Eye inflammation (scleritis, uveitis, etc.) (8)
- Giant cell arteritis (temporal arteritis) (9)
- Gout (10)
- IgG4-related disease (11)
- Juvenile idiopathic arthritis (JIA), not systemic (12)
- Systemic juvenile idiopathic arthritis (SJIA) / Still's Disease (13)
- Kawasaki disease (14)
- Lupus (15)
- Mixed connective tissue disease (16)
- Polymyalgia rheumatica (PMR) (17)
- Psoriatic arthritis (18)
- Rheumatoid arthritis (RA) (19)
- Other inflammatory arthritis (20)

- Other spondyloarthritis (including reactive arthritis) (21)
- Sarcoidosis (22)
- Sjogren's syndrome (23)
- Systemic sclerosis (scleroderma) (24)
- Undifferentiated connective tissue disease (25)
- I do not have a rheumatologic diagnosis (26)
- Other (please specify): (27) _____

Skip To: End of Survey If What is your rheumatologic disease diagnosis (check all that apply)? = I do not have a rheumatologic diagnosis

Display This Question:

If What is your rheumatologic disease diagnosis (check all that apply)? = Other inflammatory arthritis

Q5 Please specify which type of inflammatory arthritis you have:

Display This Question:

If What is your rheumatologic disease diagnosis (check all that apply)? = Autoinflammatory disease (including TRAPS, CAPS, FMF)

Q6 Please specify which autoinflammatory disease you have:

Display This Question:

If What is your rheumatologic disease diagnosis (check all that apply)? = Autoinflammatory disease (including TRAPS, CAPS, FMF)

Or What is your rheumatologic disease diagnosis (check all that apply)? = Systemic juvenile idiopathic arthritis (SJIA) / Still's Disease

Or What is your rheumatologic disease diagnosis (check all that apply)? = Lupus

X→

Q7 Have you ever had macrophage activation syndrome (MAS)?

- Yes (1)
- No (2)
- Don't know (3)



Q8 In the past 3 months, which of the following rheumatology medications have you taken? Check all that apply.

- Abatacept (Orencia) (1)
- Antimalarials (including hydroxychloroquine/Plaquenil, chloroquine) (2)
- Apremilast (Otezla) (3)
- Azathioprine / 6-MP (Imuran, mercaptopurine) (4)
- Belimumab (Benlysta) (5)
- Cyclophosphamide (Cytoxan) (6)
- Cyclosporine (Neoral/Sandimmune) (7)
- Denosumab (Prolia) (8)
- IL-1 inhibitors (including anakinra/Kineret, canakinumab/Ilaris, rilonacept/Arcalyst) (9)
- IL-6 inhibitors (including tocilizumab/Actemra, sarilumab/Kevzara, siltuximab/Sylvant) (10)
- IL-12/23 inhibitors (including ustekinumab/Stelara, guselkumab/Tremfya) (11)
- IL-17 inhibitors (including secukinumab/Cosentyx, ixekizumab/Taltz) (12)
- Intravenous immunoglobulin (IVIG) (13)
- JAK inhibitors (including tofacitinib/Xeljanz, baricitinib/Olumiant, upadacitinib/Rinvoq) (14)
- Leflunomide (Arava) (15)
- Methotrexate (Trexall) (16)
- Mycophenolate mofetil / mycophenolic acid (Cellcept, Myfortic) (17)
- Rituximab (Rituxan) (18)
- Steroids (prednisone, methylprednisolone, Medrol, etc.) (19)
- Sulfasalazine (Asulfidine) (20)

- Tacrolimus (Prograf) (21)
- Thalidomide / lenalidomide (Thalomid, Revlimid) (22)
- TNF-inhibitors (infliximab/Remicade, etanercept/Enbrel, adalimumab/Humira, golimumab/Simponi, certolizumab/Cimzia, and biosimilar versions) (23)
- None (24)
- I don't know (25)
- Other (please specify): (26) _____



Q9 In the past 3 months, have you taken any of the following other medications? Check all that apply.

- ACE inhibitor (lisinopril, captopril, ramipril, enalapril, etc) (1)
- Angiotensin receptor blocker (valsartan, losartan, candesartan, telmisartan, etc.) (2)
- Nonsteroidal anti-inflammatory drugs (NSAIDs such as ibuprofen/Motrin, naproxen/Aleve, etc, but NOT including acetaminophen/Tylenol or paracetamol) (3)
- PD5 inhibitors (Sildenafil, Viagra, Revatio, Cialis, Levitra) (4)
- Colchicine/Colcrys/Mitigare (5)
- None (6)



Q10 Have you been diagnosed with, or thought you had, COVID-19 (Coronavirus) infection?

- Yes (1)
- No (2)
- Don't know (3)

Skip To: Q26 If Have you been diagnosed with, or thought you had, COVID-19 (Coronavirus) infection? = No
Skip To: Q26 If Have you been diagnosed with, or thought you had, COVID-19 (Coronavirus) infection? = Don't know



Q11 What symptoms did you have associated with COVID-19 infection? Check all that apply.

- Fever (1)
- Malaise/fatigue (2)
- Irritability/confusion (3)
- Headache (4)
- Sore throat (5)
- Runny nose (6)
- Cough (7)
- Shortness of breath (8)
- Chest pain (9)
- Joint pain (10)
- Muscle aches (11)
- Belly pain (12)
- Diarrhea, vomiting or nausea (13)
- Loss of smell (anosmia) (14)
- Altered sense of taste (dysgeusia) (15)
- Other (please specify): (16) _____



Q12 In which month was the diagnosis of COVID-19 made?

▼ December 2019 (1) ... Prefer not to answer (13)



Q13 Where was the diagnosis of COVID-19 made?

- Home or standalone testing (e.g. drive-through testing site) (1)
- Nursing home or assisted living facility (2)
- Outpatient clinic (3)
- Emergency Department (4)
- Hospital / inpatient unit (5)
- Telehealth/telemedicine (6)
- Other (please specify): (7) _____



Q14 How was COVID-19 diagnosed?

- I diagnosed myself based on symptoms (1)
- My doctor diagnosed me based only on symptoms (2)
- My doctor diagnosed me based on positive test results (3)
- Don't know (4)
- Other (please specify): (5) _____

Display This Question:

If How was COVID-19 diagnosed? = I diagnosed myself based on symptoms

Or How was COVID-19 diagnosed? = My doctor diagnosed me based only on symptoms



Q15 Why did you not obtain testing for COVID-19?

- Testing was not available in my area (1)
- Testing was not recommended by my physician (2)
- Other (please specify): (3) _____



Q16 Have you received any of the following medications to treat COVID-19 infection? Check all that apply.

- Anti-virals (e.g. lopinavir-ritonavir/Kaletra, remdesivir) (1)
 - Anti-malarials (e.g. chloroquine, hydroxychloroquine/Plaquenil) (2)
 - Bevacizumab/Avastin (3)
 - Ciclesonide (Alvesco/Zetonna) (4)
 - Il-6 inhibitors (e.g. Tocilizumab/Actemra, sarilumab/Kevzara, siltuximab/Sylvant) (5)
 - IVIG (6)
 - JAK Kinase inhibitors ((including tofacitinib/Xeljanz, baricitinib/Olumiant, upadacitinib/Rinvoq)) (7)
 - Plasma from recovered patients (8)
 - Serpin inhibitors (9)
 - Steroids (prednisone, methylprednisone) (10)
 - Don't know (11)
 - I did not receive any treatment (12)
 - Other (please specify): (13) _____
-



Q17 Has your COVID-19 infection resolved at the time of this survey?

- Yes (1)
 - No (2)
 - Don't know (3)
-

Display This Question:

If Has your COVID-19 infection resolved at the time of this survey? = Yes



Q18 How many days did your symptoms last, from the first day you became ill until symptoms resolved?

▼ 1 (1) ... 20+ (20)

Display This Question:

If Has your COVID-19 infection resolved at the time of this survey? = No



Q19 For how many days have you been ill, counting from the first day you became ill until today?

▼ 1 (1) ... 20+ (20)



Q20 What happened during the course of your illness?

- I was not hospitalized and had no difficulties performing my daily activities (bathing, eating, dressing, etc.) (1)
- I was not hospitalized but did have some difficulties performing my daily activities (bathing, eating, dressing, etc.) (2)
- I was hospitalized but did not require oxygen (3)
- I was hospitalized and required oxygen (4)
- I was hospitalized and required non-invasive ventilation (CPAP) or high-flow oxygen devices (5)
- I was hospitalized and required a breathing machine/ventilator (6)



Q21 Did you have any of the following exposures during the 14 days before you became ill? Check all that apply.

- Travel to an area with many cases of COVID-19 infection (1)
- Close contact with a confirmed or probable case of COVID-19 infection (2)
- Presence in a healthcare facility where COVID-19 infections have been managed (3)
- Don't know (4)
- None (5)
- Other (please specify): (6) _____

Q22 How was your rheumatic disease controlled at the time that you were diagnosed with COVID-19 infection?

0 = very well

10 = very poor

0 1 2 3 4 5 6 7 8 9 10

Rheumatic disease control ()



Display This Question:

If In the past 3 months, which of the following rheumatology medications have you taken? Check all t... != None

And In the past 3 months, which of the following rheumatology medications have you taken? Check all t... != I don't know

Carry Forward Selected Choices from "In the past 3 months, which of the following rheumatology medications have you taken? Check all that apply."

X→

Q23 At the time you were diagnosed with COVID-19, had you been taking the following medications as prescribed?
If so, were the medications continued or stopped after the diagnosis?

	Yes, I was taking this medication and it was CONTINUED after diagnosis (1)	Yes, I was taking this medication, but it was STOPPED after diagnosis (2)	No, I was not taking this medication (3)	Other (4)
Abatacept (Orencia) (x2)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Antimalarials (including hydroxychloroquine/Plaquenil, chloroquine) (x3)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Apremilast (Otezla) (x4)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Azathioprine / 6-MP (Imuran, mercaptopurine) (x5)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Belimumab (Benlysta) (x6)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cyclophosphamide (Cytoxan) (x7)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cyclosporine (Neoral/Sandimmune) (x8)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Denosumab (Prolia) (x9)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-1 inhibitors (including anakinra/Kineret, canakinumab/Ilaris, rilonacept/Arcalyst) (x10)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-6 inhibitors (including tocilizumab/Actemra, sarilumab/Kevzara, siltuximab/Sylvant) (x11)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-12/23 inhibitors (including ustekinumab/Stelara, guselkumab/Tremfya) (x12)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-17 inhibitors (including secukinumab/Cosentyx, ixekizumab/Taltz) (x13)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Intravenous immunoglobulin (IVIG) (x14)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
JAK inhibitors (including tofacitinib/Xeljanz, baricitinib/Olumiant, upadacitinib/Rinvoq) (x15)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Leflunomide (Arava) (x16)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Methotrexate (Trexall) (x17)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Mycophenolate mofetil / mycophenolic acid (Cellcept, Myfortic) (x18)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rituximab (Rituxan) (x19)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Steroids (prednisone, methylprednisolone, Medrol, etc.) (x20)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Sulfasalazine (Asulfidine) (x21)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Tacrolimus (Prograf) (x22)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Thalidomide / lenalidomide (Thalomid, Revlimid) (x23)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
TNF-inhibitors (infliximab/Remicade, etanercept/Enbrel, adalimumab/Humira, golimumab/Simponi, certolizumab/Cimzia, and biosimilar versions) (x24)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<input checked="" type="radio"/> None (x1)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<input checked="" type="radio"/> I don't know (x25)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other (please specify): (x26)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Skip To: Q24 If Condition: 1 Is Selected 1. Skip To: How much steroids were you taking eve....

Display This Question:
 If At the time you were diagnosed with COVID-19, had you been taking the following medications as pr...
 Steroids (prednisone, methylprednisolone, Medrol, etc.) - Yes, I was taking this medication and it was CONTINUED
 after diagnosis Is Selected
 Or Or At the time you were diagnosed with COVID-19, had you been taking the following medications as pr...
 Steroids (prednisone, methylprednisolone, Medrol, etc.) - Yes, I was taking this medication, but it was STOPPED
 after diagnosis Is Selected



Q24 At the time you were diagnosed with COVID-19, how much steroids were you taking every day, in milligrams (mg)? If you were taking IV steroids, please enter 99.

Display This Question:

If In the past 3 months, have you taken any of the following other medications? Check all that apply. != None Carry Forward Selected Choices from "In the past 3 months, have you taken any of the following other medications? Check all that apply."



Q25 At the time you were diagnosed with COVID-19, were you taking the following drugs? If so, were they continued after diagnosis?

	Yes, and this medication was CONTINUED (1)	Yes, and this medication was STOPPED at diagnosis (2)	No, I was not taking this medication (3)	Don't know (4)
ACE inhibitor (lisinopril, captopril, ramipril, enalapril, etc) (x1)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Angiotensin receptor blocker (valsartan, losartan, candesartan, telmisartan, etc.) (x2)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Nonsteroidal anti-inflammatory drugs (NSAIDs such as ibuprofen/Motrin, naproxen/Aleve, etc, but NOT including acetaminophen/Tylenol or paracetamol) (x3)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
PD5 inhibitors (Sildenafil, Viagra, Revatio, Cialis, Levitra) (x4)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Colchicine/Colcrys/Mitigare (x5)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<input checked="" type="checkbox"/> None (x6)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Page Break



Q26 Over the past 30 days, what methods have you been using to protect yourself from COVID-19?

- Social distancing (avoiding crowds and large groups of people) (1)
- Quarantine (staying home and avoiding others as much as possible) (2)
- Using gloves and/or masks during social interactions (3)
- None (4)
- Other (please specify): (5) _____

Display This Question:

If Over the past 30 days, what methods have you been using to protect yourself from COVID-19? = Quarantine (staying home and avoiding others as much as possible)



Q27 Who made the decision for quarantine?

- Myself (1)
- Imposed by my city/state/province/country (2)
- Don't know (3)



Q28 In the last 30 days, have you participated in any of the following activities? Check all that apply

- Travel to an area with many cases of COVID-19 infection (2)
- Close contact with a confirmed or probable case of COVID-19 infection (3)
- Presence in a healthcare facility where COVID-19 infections have been managed (4)
- None (1)
- Don't know (5)
- Other (please specify): (6) _____

Display This Question:

If In the past 3 months, which of the following rheumatology medications have you taken? Check all t... != None

And In the past 3 months, which of the following rheumatology medications have you taken? Check all t... != I don't know

Carry Forward Selected Choices from "In the past 3 months, which of the following rheumatology medications have you taken? Check all that apply."

X→

Q29 Do you continue to take the following medications as prescribed? If not, why not?

	Yes, I continue to take this drug (1)	No, pharmacy did not have supply (2)	No, it was not effective (3)	No, I want to avoid immunosuppression (4)
Abatacept (Orencia) (x2)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Antimalarials (including hydroxychloroquine/Plaquenil, chloroquine) (x3)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Apremilast (Otezla) (x4)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Azathioprine / 6-MP (Imuran, mercaptopurine) (x5)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Belimumab (Benlysta) (x6)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cyclophosphamide (Cytosan) (x7)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cyclosporine (Neoral/Sandimmune) (x8)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Denosumab (Prolia) (x9)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-1 inhibitors (including anakinra/Kineret, canakinumab/Ilaris, rilonacept/Arcalyst) (x10)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-6 inhibitors (including tocilizumab/Actemra, sarilumab/Kevzara, siltuximab/Sylvant) (x11)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-12/23 inhibitors (including ustekinumab/Stelara, guselkumab/Tremfya) (x12)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-17 inhibitors (including secukinumab/Cosentyx, ixekizumab/Taltz) (x13)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Intravenous immunoglobulin (IVIG) (x14)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
JAK inhibitors (including tofacitinib/Xeljanz, baricitinib/Olumiant, upadacitinib/Rinvoq) (x15)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Leflunomide (Arava) (x16)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Methotrexate (Trexall) (x17)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Mycophenolate mofetil / mycophenolic acid (Cellcept, Myfortic) (x18)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rituximab (Rituxan) (x19)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Steroids (prednisone, methylprednisolone, Medrol, etc.) (x20)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Sulfasalazine (Asulfidine) (x21)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Tacrolimus (Prograf) (x22)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Thalidomide / lenalidomide (Thalomid, Revlimid) (x23)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
TNF-inhibitors (infliximab/Remicade, etanercept/Enbrel, adalimumab/Humira, golimumab/Simponi, certolizumab/Cimzia, and biosimilar versions) (x24)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<input checked="" type="radio"/> None (x1)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<input checked="" type="radio"/> I don't know (x25)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other (please specify): (x26)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Display This Question:

If Do you continue to take the following medications as prescribed? If not, why not? = No, I want to avoid immunosuppression

Or Or Do you continue to take the following medications as prescribed? If not, why not? Abatacept (Orencia) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Antimalarials (including hydroxychloroquine/Plaquenil, chloroquine) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Apremilast (Otezla) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Azathioprine / 6-MP (Imuran, mercaptopurine) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Belimumab (Benlysta) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Cyclophosphamide (Cytosan) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Cyclosporine (Neoral/Sandimmune) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Denosumab (Prolia) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? IL-1 inhibitors (including anakinra/Kineret, canakinumab/Ilaris, rilonacept/Arcalyst) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? IL-6 inhibitors (including tocilizumab/Actemra, sarilumab/Kevzara, siltuximab/Sylvant) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? IL-12/23 inhibitors (including ustekinumab/Stelara, guselkumab/Tremfya) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? IL-17 inhibitors (including secukinumab/Cosentyx, ixekizumab/Taltz) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Intravenous immunoglobulin (IVIG) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? JAK inhibitors (including tofacitinib/Xeljanz, baricitinib/Olumiant, upadacitinib/Rinvoq) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Leflunomide (Arava) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Methotrexate (Trexall) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Mycophenolate mofetil / mycophenolic acid (Cellcept, Myfortic) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Rituximab (Rituxan) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Steroids (prednisone, methylprednisolone, Medrol, etc.) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Sulfasalazine (Asulfidine) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Tacrolimus (Prograf) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? Thalidomide / lenalidomide (Thalomid, Revlimid) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? TNF-inhibitors (infliximab/Remicade, etanercept/Enbrel, adalimumab/Humira, golimumab/Simponi, certolizumab/Cimzia, and biosimilar versions) - No, I want to avoid immunosuppression Is Selected

Or Or Do you continue to take the following medications as prescribed? If not, why not? TNF-inhibitors (infliximab/Remicade, etanercept/Enbrel, adalimumab/Humira, golimumab/Simponi, certolizumab/Cimzia, and biosimilar versions) - No, I want to avoid immunosuppression Is Selected

Carry Forward Selected Choices from "Do you continue to take the following medications as prescribed? If not, why not?"



Q30 Who decided to decrease or stop the following immunosuppressive drugs?

	My rheumatologist recommended it (1)	I decided to change my medication and told my rheumatologist about it (2)	I decided to change my medication and DID NOT tell my rheumatologist about it (3)
Abatacept (Orencia) (xx2)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Antimalarials (including hydroxychloroquine/Plaquenil, chloroquine) (xx3)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Apremilast (Otezla) (xx4)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Azathioprine / 6-MP (Imuran, mercaptopurine) (xx5)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Belimumab (Benlysta) (xx6)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cyclophosphamide (Cytoxan) (xx7)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cyclosporine (Neoral/Sandimmune) (xx8)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Denosumab (Prolia) (xx9)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-1 inhibitors (including anakinra/Kineret, canakinumab/Ilaris, rilonacept/Arcalyst) (xx10)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-6 inhibitors (including tocilizumab/Actemra, sarilumab/Kevzara, siltuximab/Sylvant) (xx11)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-12/23 inhibitors (including ustekinumab/Stelara, guselkumab/Tremfya) (xx12)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IL-17 inhibitors (including secukinumab/Cosentyx, ixekizumab/Taltz) (xx13)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Intravenous immunoglobulin (IVIG) (xx14)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
JAK inhibitors (including tofacitinib/Xeljanz, baricitinib/Olumiant, upadacitinib/Rinvoq) (xx15)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>


Leflunomide (Arava) (xx16)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Methotrexate (Trexall) (xx17)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Mycophenolate mofetil / mycophenolic acid (Cellcept, Myfortic) (xx18)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rituximab (Rituxan) (xx19)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Steroids (prednisone, methylprednisolone, Medrol, etc.) (xx20)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Sulfasalazine (Asulfidine) (xx21)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Tacrolimus (Prograf) (xx22)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Thalidomide / lenalidomide (Thalomid, Revlimid) (xx23)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
TNF-inhibitors (infliximab/Remicade, etanercept/Enbrel, adalimumab/Humira, golimumab/Simponi, certolizumab/Cimzia, and biosimilar versions) (xx24)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<input checked="" type="radio"/> None (xx1)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<input checked="" type="radio"/> I don't know (xx25)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other (please specify): (xx26)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>



Q31 In the past 30 days, how have you communicated with your rheumatologist? Check all that apply.

- I have not needed to communicate with my rheumatologist (1)
- Phone call (2)
- Email / patient portal (3)
- Telemedicine / Videoconference (4)
- Office visit (5)
- I have not been able to communicate with my rheumatologist through any methods (6)
- Other (please specify): (7) _____

Q32 Considering all the ways your rheumatic disease affects you, rate how well you are doing TODAY on the following scale:



Display This Question:

If Will you be completing the survey for yourself, or on behalf of your child with rheumatic disease? = For my child

Q33 Remember, even though we're asking questions about "YOU," please enter the following information about YOUR CHILD.



Q34 How old are you?



Q35 What is your gender?

- Male (1)
- Female (2)
- Prefer not to answer (3)
- Other (please specify): (4) _____

Display This Question:

*If If How old are you? Text Response Is Greater Than 12
And And How old are you? Text Response Is Less Than 50*

X+

Q36 Are you, or have you been pregnant in the last 6 weeks?

- Not applicable (1)
- I am currently pregnant (2)
- I was pregnant less than 6 weeks ago (3)
- I'm not pregnant (4)
- Don't know (5)
- Prefer not to answer (6)

Display This Question:

*If If How old are you? Text Response Is Greater Than 12
And And How old are you? Text Response Is Less Than 50
And Have you been diagnosed with, or thought you had, COVID-19 (Coronavirus) infection? = Yes*

X+

Q37 At the time you were diagnosed with COVID-19, were you pregnant or within 6 weeks of pregnancy?

- Not applicable (1)
- I was pregnant (2)
- I was within 6 weeks of my pregnancy (3)
- I was not pregnant (4)
- Don't know (5)
- Prefer not to answer (6)



Q38 In what country do you live?

▼ Afghanistan (1) ... Zimbabwe (199)

Display This Question:

If In what country do you live? = United States of America (USA)



Q39 In what state do you live?

▼ Alabama (1) ... Wyoming (51)

Display This Question:

If Will you be completing the survey for yourself, or on behalf of your child with rheumatic disease? = For my child

Q71 Remember, even though we're asking questions about "YOU," please enter the following information about YOUR CHILD.



Q40 What is your race or ethnic origin (Check all that apply)

- Arab (1)
 - Black (2)
 - East Asian (3)
 - South Asian (4)
 - West Asian (5)
 - Pacific Islander (6)
 - Latin American (7)
 - White (8)
 - Native American / Aboriginal / 1st Nations (9)
 - Don't know (10)
 - Prefer not to answer (11)
 - Other (please specify): (12) _____
-



Q41 Do you, or have you smoked tobacco?

- Yes, I am a current tobacco smoker (1)
 - Yes, I am a former tobacco smoker (2)
 - No, I never smoked (3)
-



Q42 Do you, or have you used vaping products or e-cigarettes?

- Yes, I am a current user (1)
 - Yes, I am a former user (2)
 - No, I never used those products (3)
-



Q43 Do you have any of the following medical conditions? Check all that apply

- Asthma, emphysema, or COPD (1)
- Cancer (2)
- Chronic kidney disease (3)
- Chronic neurological or neuromuscular disease (multiple sclerosis, ALS, etc.) (4)
- Diabetes (5)
- Fibromyalgia / amplified musculoskeletal pain syndrome (AMPS) (6)
- Heart disease (heart attack, congestive heart failure, etc.) (7)
- High blood pressure (8)
- High blood pressure in the lungs (pulmonary hypertension) (9)
- Immunodeficiency (10)
- Inflammatory bowel disease (Crohn's disease or Ulcerative colitis) (11)
- Interstitial lung disease (e.g. nonspecific interstitial pneumonia, idiopathic pulmonary fibrosis, etc.) (12)
- Liver disease (13)
- Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (14)
- Other lung disease (15)
- Organ transplant recipient (16)
- Psychiatric condition (schizophrenia, bipolar, etc.) (17)
- Severe obesity (18)
- Trisomy 21 (19)
- None (20)

Don't know (21)

Other (please specify): (22) _____



Q44 On January 1, 2020, what was your employment or student status?

- Employed full time (1)
- Employed part-time (2)
- Not employed, looking for work (3)
- Not employed, NOT looking for work (4)
- Retired (5)
- Disabled, not able to work (6)
- Full-time student (7)

Display This Question:

If On January 1, 2020, what was your employment or student status? != Full-time student



Q45 Has your employment or student status changed as a result of the COVID-19 pandemic?

- Yes (1)
- No (2)
- Don't know (3)

Display This Question:

If On January 1, 2020, what was your employment or student status? = Full-time student



Q46 How are you now participating in classes?

- I attend classes in the classroom (1)
- I attend classes virtually in the computer (2)
- Classes were cancelled (3)
- Other (please specify): (4) _____

Display This Question:

If Has your employment or student status changed as a result of the COVID-19 pandemic? = Yes

X→

Q47 What is your current employment or student status?

- Employed full time (1)
- Employed part-time (2)
- Not employed, looking for work (3)
- Not employed, NOT looking for work (4)
- Retired (5)
- Disabled, not able to work (6)
- Full-time student (7)

Display This Question:

If Will you be completing the survey for yourself, or on behalf of your child with rheumatic disease? = For myself (adult aged 18 and over)

X→

Q48 Please respond to each question or statement by checking one box per row

	Excellent (1)	Very good (2)	Good (3)	Fair (4)	Poor (5)
In general, how would you rate your mental health, including your mood and your ability to think? (1)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
In general, how would you rate your satisfaction with your social activities and relationships? (2)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
In general, how would you rate your physical health? (6)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Display This Question:

If Will you be completing the survey for yourself, or on behalf of your child with rheumatic disease? = For myself (adult aged 18 and over)



Q49 Please respond to each question or statement by checking one box per row

	Completely (1)	Mostly (2)	Moderately (3)	A little (4)	Not at all (5)
To what extent are you able to carry out your everyday physical activities such as walking, climbing stairs, carrying groceries, or moving a chair? (1)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Display This Question:

If Will you be completing the survey for yourself, or on behalf of your child with rheumatic disease? = For my child



Q50 Please respond to each question or statement by checking one box per row

	Excellent (1)	Very good (2)	Good (3)	Fair (4)	Poor (5)
In general, would you say your child's health is... (1)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
In general, would you say your child's quality of life is... (2)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
In general, how would you rate your child's physical health? (6)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
In general, how would you rate your child's mental health, including mood and ability to think? (7)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Display This Question:

If Will you be completing the survey for yourself, or on behalf of your child with rheumatic disease? = For my child



Q51 Please respond to each question or statement by checking one box per row

	Never (1)	Rarely (2)	Sometimes (3)	Often (4)	Always (5)
How often does your child feel really sad? (1)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
How often does your child have fun with friends? (11)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
How often does your child feel that you listen to his or her ideas? (12)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>



Q52 Do you belong to any of the following patient-support organizations? Check all that apply

- American Behcet's Disease Foundation (ABDA) (1)
- Arthritis Consumer Experts (2)
- Arthritis Foundation (3)
- Arthritis Life (4)
- Association of Rheumatology Concerns (5)
- Autoinflammatory Alliance (6)
- CARRA (7)
- CreakyJoints (8)
- CureJM (9)
- Deutsche Rheuma-Liga (10)
- Disability Federation of Ireland (11)
- EULAR PARE (50)
- Foundation for Sarcoidosis Research (12)
- Hospital Clinic, Barcelona, Spain (13)
- Hospital Especialidades Centro Médico Nacional IMSS (14)
- Instituto de Investigación Hospital 12 de Octubre (RIER, Red de Investigación en Inflamación y Enfermedades Reumáticas) (15)
- International Foundation for Autoimmune & Autoinflammatory Arthritis (49)
- Iran University of Medical Sciences (16)
- JIA Matters (17)
- Juvenile Arthritis Research (JAR) (48)

- Klinik für Kinder- und Jugendmedizin I des UKSH, Campus Kiel (18)
- Lupus Foundation of America (19)
- Mayo Clinic Health System (20)
- Medical University of Lodz, Department of Rheumatology, (21)
- Mifrakim Tz'eirim (22)
- Norwegian Rheumatism Association (23)
- Ontario Rheumatology Association (24)
- Piedmont Healthcare - Piedmont Atlanta Rheumatology (25)
- Psoriasis and Psoriatic Arthritis Alliance (PAPAA) (26)
- RA chicks (27)
- RareConnect (28)
- Rheumatology Specialists of Connecticut, Inc. (29)
- Rheumatology UKE Hamburg (30)
- Rhumatologie Hopital Maisonneuve-Rosemont (31)
- Scleroderma Clinical Trials Consortium (32)
- Sociedad Chilena de Reumatología (SOCHIRE) (33)
- Spanish Society of Rheumatology (34)
- St James's Hospital (35)
- Stowarzyszenie "3majmy się razem" (36)
- Spondylitis Association of America (37)
- Systemic JIA Foundation (38)

- The Polyclinic (39)
 - UK National Rheumatoid Arthritis Society (NRAS) (40)
 - Universita Politecnica Delle Marche (41)
 - University of Michigan (42)
 - Vasculitis UK (43)
 - Versus Arthritis (44)
 - Women with Rheumatoid Disease (45)
 - None (46)
 - Other (please specify): (47) _____
-

Q53 Do you have any other questions, comments, or concerns? We'd love to hear your feedback!

End of Block: Default Question Block

Categorisation of rheumatic diseases

Rheumatic diseases were categorised as: rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, psoriatic arthritis, antiphospholipid syndrome, spondyloarthritis (including ankylosing spondylitis/axial spondyloarthritis, reactive arthritis, and other spondyloarthritis), vasculitis (anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, giant cell arteritis/polymyalgia rheumatica, polyarteritis nodosa, and Behcet's syndrome), other connective tissue disease (idiopathic inflammatory myopathy, mixed connective tissue disease, systemic sclerosis, and undifferentiated connective tissue disease), autoinflammatory disease (chronic recurrent multifocal osteomyelitis, systemic juvenile idiopathic arthritis, adult-onset Still's disease, and other genetic autoinflammatory syndromes), and other arthritis (adults with juvenile idiopathic arthritis and other arthritis not included above).

Categorisation of medications

Medications were grouped as follows: systemic glucocorticoids; conventional synthetic disease-modifying antirheumatic drugs (csDMARDs): antimalarials (hydroxychloroquine and chloroquine), azathioprine, mercaptopurine, cyclophosphamide, cyclosporine, leflunomide, methotrexate, mycophenolate mofetil, and mycophenolic acid; biologic DMARDs (bDMARDs): abatacept, belimumab, IL-1 Inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, IL-6 inhibitors, CD20 inhibitors, and TNF-inhibitors; targeted synthetic DMARDs (tsDMARDs): Janus kinase (JAK) Inhibitors. "Other" medications included apremilast, intravenous immunoglobulin (IVIG), thalidomide, and lenalidomide.

Categorisation of comorbidities

Comorbidities were also grouped into categories: cardiovascular disease (hypertension and heart disease), pain syndromes (fibromyalgia/amplified musculoskeletal pain syndrome and myalgic encephalomyelitis/chronic fatigue syndrome), pulmonary disease (asthma/emphysema/chronic obstructive pulmonary disease, pulmonary hypertension, interstitial lung disease, and other lung diseases), immunologic (immunodeficiency and organ transplant recipient), obesity-related conditions, gastrointestinal (inflammatory bowel disease, liver and celiac disease, and other gastrointestinal conditions), endocrinologic (thyroid and bone diseases and diabetes), psychiatric, renal (chronic kidney disease), neurologic (chronic neurological or neuromuscular diseases), dermatologic (psoriasis), malignant, hematologic (Von Willebrand disease and other hematological conditions), congenital/genetic (Trisomy 21 and Ehlers-Danlos syndrome) and ocular.

Supplementary Table 1. Additional clinical characteristics from the COVID-19 Global Rheumatology Alliance Patient Experience Survey (N= total number of respondents per question).

	Total Respondents, n (%)	Female, n (%)	Male, n (%)	Other, n (%)
Comorbidities*	N=8,923	N = 8375	N=893	N=32
<i>Cardiovascular</i>	2241 (25.1)	1965 (24.4)	274 (32.5)	2 (6.7)
<i>Pain syndrome</i>	1901 (21.3)	1843 (22.9)	53 (6.3)	5 (16.7)
<i>Pulmonary</i>	1819 (20.4)	1690 (21.0)	125 (14.8)	4 (13.3)
<i>Immunologic</i>	990 (11.1)	917 (11.4)	70 (8.3)	3 (10.0)
<i>Obesity</i>	652 (7.3)	609 (7.6)	41 (4.9)	2 (6.7)
<i>Gastrointestinal</i>	650 (7.3)	575 (7.1)	72 (8.5)	3 (10.0)
<i>Endocrinologic</i>	488 (5.5)	419 (5.2)	67 (7.9)	2 (6.7)
<i>Psychiatric</i>	422 (4.7)	395 (4.9)	25 (3.0)	2 (6.7)
<i>Renal</i>	417 (4.7)	387 (4.8)	30 (3.6)	0 (0)
<i>Neurologic</i>	228 (2.6)	210 (2.6)	16 (1.9)	2 (6.7)
<i>Dermatologic</i>	191 (2.1)	155 (1.9)	35 (4.2)	1 (3.3)
<i>Malignancy</i>	112 (1.3)	93 (1.2)	19 (2.3)	0 (0.0)
<i>Hematologic</i>	15 (0.2)	15 (0.2)	0 (0.0)	0 (0.0)
<i>Congenital/genetic</i>	7 (0.1)	7 (0.1)	0 (0.0)	0 (0.0)
<i>Ocular</i>	4 (0.0)	4 (0.0)	0 (0.0)	0 (0.0)
<i>None</i>	2889 (32.4)	2568 (31.9)	311 (36.9)	10 (33.3)
Vaping/e-cigarette Use Status	N=9,266	N=8,347	N=889	N=30
<i>Current</i>	348 (3.8)	301 (3.6)	44 (4.9)	3 (10.0)
<i>Past</i>	512 (5.5)	428 (5.1)	80 (9.0)	4 (13.3)
<i>Never</i>	8406 (90.7)	7618 (91.3)	765 (86.1)	23 (76.7)
Communication with a Rheumatologist*	N=9,270	N=8,346	N=892	N=32
<i>Telephone</i>	2252 (24.3)	2029 (24.3)	218 (24.4)	5 (15.6)
<i>Email/patient portal</i>	1611 (17.4)	1470 (17.6)	135 (15.1)	6 (18.8)
<i>Office visit</i>	919 (9.9)	829 (9.9)	90 (10.1)	0 (0.0)
<i>Telemedicine</i>	552 (6.0)	507 (6.1)	44 (4.9)	1 (3.1)
<i>Other (social media/texting)</i>	773 (8.3)	726 (8.7)	44 (4.9)	3 (9.4)
<i>Not needed to communicate</i>	3291 (35.5)	2932 (35.1)	345 (38.7)	14 (43.8)
<i>Unable to communicate</i>	1043 (11.3)	939 (11.3)	100 (11.2)	4 (12.5)
Protective Behaviours*	N=9,297	N=8,372	N=893	N=32
<i>Quarantining</i>	7952 (85.5)	7210 (86.1)	717 (80.3)	25 (78.1)
<i>Specified reason for decision</i>	7935 (99.8)	7195 (99.8)	716 (99.9)	24 (96.0)
<i>Government imposed</i>	4056 (51.1)	3702 (51.5)	339 (47.3)	15 (62.5)
<i>Self-imposed</i>	6228 (78.5)	5648 (78.5)	562 (78.5)	18 (75.0)
<i>Unknown</i>	19 (0.2)	15 (0.2)	4 (0.6)	0 (0.0)
<i>Social distancing</i>	7206 (77.5)	6476 (77.4)	706 (79.1)	24 (75.0)
<i>Using gloves and/or masks</i>	4631 (49.8)	4196 (50.1)	419 (46.9)	16 (50.0)
<i>Other</i>	791 (8.5)	731 (8.7)	55 (6.2)	5 (15.6)
<i>None</i>	31 (0.3)	27 (0.3)	3 (0.3)	1 (3.1)
<i>Any protective behaviour</i>	9266 (99.7)	8345 (99.7)	890 (99.7)	31 (96.9)
<i>All protective behaviours (quarantining, social distancing, and using gloves/masks)</i>	3620 (38.9)	3298 (39.4)	307 (34.4)	15 (46.9)
Risky Behaviours*	N=9,179	N=8,268	N=881	N=30
<i>Presence in healthcare facility</i>	1228 (13.4)	1117 (13.5)	108 (12.3)	3 (10.0)
<i>Close contact with confirmed/probable case of COVID-19</i>	394 (4.3)	361 (4.4)	31 (3.5)	2 (6.7)

<i>Travel to area of high COVID-19 prevalence</i>	365 (4.0)	306 (3.7)	58 (6.6)	1 (3.3)
<i>Other (workplace, shopping, public transit, secondary transmission from family/friends)</i>	477 (5.2)	438 (5.3)	38 (4.3)	1 (3.3)
<i>None</i>	6340 (69.1)	5712 (69.1)	609 (69.1)	19 (63.3)
<i>Don't know</i>	775 (8.4)	697 (8.4)	74 (8.4)	4 (13.3)
<i>Any risky behaviour</i>	2104 (22.9)	1898 (23.0)	199 (22.6)	7 (23.3)
<i>1 risky behaviour</i>	1781 (84.6)	1605 (84.6)	169 (84.9)	7 (100.0)
<i>2 risky behaviours</i>	290 (13.8)	266 (14.0)	24 (12.1)	0 (0.0)
<i>3+ risky behaviours</i>	33 (1.6)	27 (1.4)	6 (3.0)	0 (0.0)
Antirheumatic Medication Usage Patterns	N=8,441	N=7,637	N=777	N=27
<i>Continued medications as prescribed</i>	6921 (82.0)	6247 (81.8)	655 (84.3)	19 (70.4)
<i>Discontinued due to lack of efficacy, lack of pharmacy supply, or desire to avoid immunosuppression.</i>	1520 (18.0)	1390 (18.2)	122 (15.7)	8 (29.6)
Full-time students	N=301	N=273	N=24	N=2
<i>Transitioned to virtual classes</i>	207 (68.8)	188 (68.9)	18 (75.0)	1 (50.0)
<i>Classes cancelled</i>	52 (17.3)	49 (17.9)	3 (12.5)	0 (0.0)
<i>Continued attending classes in person</i>	5 (1.7)	4 (1.5)	0 (0.0)	1 (50.0)
<i>Other changes (e.g., completed classes)</i>	35 (11.6)	32 (11.7)	3 (12.5)	0 (0.0)
<i>Missing</i>	2 (0.7)			

The N totals listed for each section represent the total number of respondents who answered the corresponding questions. The outstanding respondents from the total of 9,300 were either not shown the question due to branching logic or chose not to answer.

*Participants may indicate more than one comorbidity, method of communication with a rheumatologist, protective behaviors, and risky behaviors.

Supplementary Table 2.a. Patient responses on employment status as of January 1, 2020.

	Total, n (%)	Female, n (%)	Male, n (%)	Other, n (%)
Employment status (N)	9,300	8375	893	32
Disabled, not able to work	1,321 (14.2)	1206 (14.4)	110 (12.3)	5 (15.6)
Employed full time	4,066 (43.7)	3564 (42.6)	494 (55.3)	8 (25.0)
Employed part-time	1,434 (15.4)	1356 (16.2)	70 (7.8)	8 (25.0)
Full-time student	301 (3.2)	275 (3.3)	24 (2.7)	2 (6.2)
Not employed, looking for work	384 (4.1)	349 (4.2)	32 (3.6)	3 (9.4)
Not employed, NOT looking for work	674 (7.2)	656 (7.8)	15 (1.7)	3 (9.4)
Retired	1,120 (12.0)	969 (11.6)	148 (16.6)	3 (9.4)

Supplementary Table 2.b. Patient responses on employment status at the time of the survey.

	Total, n (%)	Female, n (%)	Male, n (%)	Other, n (%)
Employment status (N)	9,300	8375	893	32
Disabled, not able to work	1,405 (15.1)	1283 (15.3)	114 (12.8)	6 (18.8)
Employed full time	3,514 (37.8)	3024 (36.1)	428 (47.9)	7 (21.9)
Employed part-time	1,377 (14.8)	1252 (14.9)	86 (9.6)	7 (21.9)
Full-time student	318 (3.4)	291 (3.5)	25 (2.8)	2 (6.2)
Not employed, looking for work	540 (5.8)	487 (5.8)	47 (5.3)	4 (12.5)
Not employed, NOT looking for work	1,020 (11.0)	982 (11.7)	32 (3.6)	3 (9.4)
Retired	1,126 (12.1)	970 (11.6)	150 (16.8)	3 (9.4)

Manuscript Contributors

GRA Steering Committee members

Suleman Bhana, Crystal Run Health, Middletown, NY, USA

Wendy Costello, Irish Children's Arthritis Network (iCAN), Tipperary, Ireland

Rebecca Grainger, Department of Medicine, University of Otago, Wellington, New Zealand

Jonathan S. Hausmann, Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center; Program in Rheumatology, Division of Immunology, Boston Children's Hospital; Harvard Medical School, Boston, MA, USA

Jean W. Liew, Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Seattle, WA, USA

Pedro M. Machado, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals National Health Service (NHS) Foundation Trust, London, UK; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK

Philip C. Robinson, Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia

Emily Sirotych, Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, ON, Canada; Canadian Arthritis Patient Alliance, Toronto, ON, Canada

Paul H. Sufka, HealthPartners, St. Paul, MN, USA

Zachary S. Wallace, Clinical Epidemiology Program, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital; Harvard Medical School, Boston, MA, USA

Jinoos Yazdany, Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA

GRA Patient Board members

Wendy Costello, Irish Children's Arthritis Network (iCAN), Tipperary, Ireland

Monique C. Gore-Massy, Lupus Foundation of America, Brooklyn, NY, USA

Carly O. Harrison, LupusChat, New York, NY, USA

Richard A. Howard, Spondylitis Association of America, Encino, CA, USA

Moré A. Kodek, Lupus Foundation of Kenya, Nairobi, Kenya

Emily Sirotych, Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, ON, Canada; Canadian Arthritis Patient Alliance, Toronto, ON, Canada

Laura-Ann Tomasella, Arthritis Kids South Africa, South Africa

John Wallace, Autoinflammatory UK, Scotland

McMaster University internal team members

Barbara Baker, Division of Rheumatology, Department of Medicine, McMaster University

Gary Foster, Department of Health Research Methods, Evidence, and Impact (HEI), Department of Medicine, McMaster University

Carly O. Harrison, LupusChat, New York, NY, USA

Jonathan S. Hausmann, Division of Rheumatology and Clinical Immunology, Boston Children's Hospital; Beth Israel Deaconess Medical Center; Harvard Medical School, Boston, MA, USA

Kevin Kennedy, Department of Health Research Methods, Evidence and Impact (HEI), McMaster University

Maggie J. Larché, Divisions of Rheumatology/Clinical Immunology and Allergy, Department of Medicine, McMaster University

Mitchell Levine, Department of Health Research Methods, Evidence, and Impact (HEI); Medicine; Clinical Pharmacology & Toxicology, McMaster University

Tarin T. Moni, Department of Biochemistry & Biomedical Sciences, McMaster University

Sebastian E. Sattui, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA

Teresa Semalulu, Department of Medicine, McMaster University

Julia F. Simard, Department of Epidemiology and Population Health and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA

Emily Sirotych, Department of Health Research Methods, Evidence and Impact (HEI), McMaster University; Canadian Arthritis Patient Alliance, Toronto, ON, Canada

Jeffrey A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
Salman Surangiwalla, School of Medicine, Queen's University, Kingston, ON, Canada
Lehana Thabane, Department of Health Research Methods, Evidence and Impact (HEI), McMaster University

External project contributors

Ibrahim Almaghlouth, King Saud University, Riyadh, Saudi Arabia
Saskya Angevare, KAISZ, Netherlands
Richard P. Beesley, Juvenile Arthritis Research; European Network for Childhood Arthritis (ENCA), Tonbridge, UK
Francis Berenbaum, Sorbonne Université, INSERM, AP-HP Saint-Antoine Hospital, Paris, France
Yu Pei Eugenia Chock, Yale School of Medicine, New Haven, CT, USA
Eileen Davidson, Arthritis Research Canada, Arthritis Society, Vancouver, BC, Canada
Sarah L. Dillingham, Women with Rheumatoid Disease, Seattle, WA, USA
Karen L. Durrant, Autoinflammatory Alliance, San Francisco, CA, USA
Alia El-Qunni, Patient advocate, St. Louis, MO, USA
Lina El Kibbi, Arab Adult Arthritis Awareness Group (AAAA Group), Riyadh, Saudi Arabia
Christele Felix, LupusChat, New York, NY, USA
Catherine L. Hill, Rheumatology Unit, The Queen Elizabeth Hospital, Woodville South, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia
Bimba F. Hoyer, Department for Rheumatology and Clinical Immunology, Medizinische Klinik, Evelyn Hsieh, Yale School of Medicine, New Haven, CT, USA
Naira Ikram, Duke University, Durham, NC, USA
Lindsay R. Jacobsohn, University of California San Francisco, San Francisco, CA, USA
Cheryl L. Koehn, Arthritis Consumer Experts, Vancouver, BC, Canada
Lynn R. Laidlaw, Versus Arthritis, UK
Jan Leipe, Division of Rheumatology, Department of Medicine, University Hospital, Mannheim, Germany
David F.L. Liew, Department of Rheumatology, Austin Health, Heidelberg, Australia
Maria A. Marino, RA Chicks: Women with arthritis, Athens, GA, USA
Elsa F. Mateus, Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Comprehensive Health Research Centre (CHRC), Lisbon, Portugal
Serena Mingolla, Italian National Association of People with Rheumatic and Rare Diseases (APMARR), Brindisi, Italy
Michal Nudel, The Israeli association for RMDs patients "Mifrakim Tz'eirim", Haifa, Israel
Evelyn Olmedo, Patient advocate, Buenos Aires, El Salvador
Candace A. Palmerlee, Patient Advocate, Relapsing Polychondritis Foundation, International Relapsing Polychondritis Research Network, Walnut Creek, CA, USA
Andrea Peirce, Patient advocate, New York, NY, USA
Linyi Peng, Peking Union Medical College Hospital, Beijing, China
Cecilia N. Pisoni, CEMIC, Argentina
Laurie Proulx, Canadian Arthritis Patient Alliance, Ottawa, Canada; Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany
Graeme Reed, Canadian Spondylitis Association, Ottawa, ON, Canada
Dawn P. Richards, Canadian Arthritis Patient Alliance, Toronto, Canada
Cecilia Rodriguez, Universidad Mayor, Chile
Catalina Sanchez-Alvarez, University of Florida, Gainesville, FL, USA
Rashmi Sinha, Systemic JIA Foundation, Cincinnati, OH, USA
Katie Hutton Sundgren, Patient advocate
Leslie Yingzhijie Tseng, Yale School of Medicine, New Haven, CT, USA
Ana Vieira, Patient research partner, Grupo Moldoeste, Leiria, Portugal
Tiffany Westrich-Robertson, International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis), St. Louis, MO, USA
Di Wu, Peking Union Medical College Hospital, Beijing, China
Kristen J. Young, University of Texas Southwestern Medical Center, Dallas, TX, USA
Erick Zamora-Tehozol, Colegio Mexicano de Reumatología, Centro Médico Pensiones, México